InsiderTrades

Form 4 for REGN Regeneron Pharmaceuticals

Accepted 2021-12-10 00:00:00 ET · period of report 2021-12-08 · accession 0001883850-21-000023 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2021-12-10 2021-12-09 REGN LAROSA JOSEPH J EVP GC, Secret M - OptEx $179.13 +30.0K 46.5K +182% +$5.37M
D 2021-12-10 2021-12-09 REGN LAROSA JOSEPH J EVP GC, Secret F - Tax $657.11 -19.8K 26.7K -43% -$12.99M
D 2021-12-10 2021-12-08 REGN LAROSA JOSEPH J EVP GC, Secret A - Grant $0.00 +3,338 16.5K +25% $0
D 2021-12-10 2021-12-09 REGN LAROSA JOSEPH J EVP GC, Secret M - OptEx $0.00 -30.0K 0 -100% $0
D 2021-12-10 2021-12-08 REGN LAROSA JOSEPH J EVP GC, Secret A - Grant $0.00 +14.3K 14.3K New $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2021-12-09 M A 30,000 $179.13 46,520 D — —
2 Common Common Stock 2021-12-09 F D 19,772 $657.11 26,748 D — —
3 Common Common Stock 2021-12-08 A A 3,338 $0.00 16,520 D — —
4 Derivative Non-Qualified Stock Option (right to buy) 2021-12-09 M D 30,000 $0.00 0 D $179.13 · — to 2022-12-14 30,000 Common Stock (F2) The stock option award vests in four equal annual installments, commencing one year after the date of grant.
5 Derivative Non-Qualified Stock Option (right to buy) 2021-12-08 A A 14,253 $0.00 14,253 D $644.54 · — to 2031-12-08 14,253 Common Stock (F2) The stock option award vests in four equal annual installments, commencing one year after the date of grant.